Check for updates

OPEN ACCESS

EDITED BY Ivana Šarac, Institute for Medical Research, University of Belgrade, Serbia

REVIEWED BY

Sepideh Mahboobi, Shiraz University of Medical Sciences, Iran Khaled Baagar, Hamad Medical Corporation, Qatar Per Bendix Jeppesen, Aarhus University, Denmark

*Correspondence Bo Li I bo@ilu.edu.cn

Frontiers in Nutrition

SPECIALTY SECTION This article was submitted to Clinical Nutrition, a section of the journal

RECEIVED 01 July 2022 ACCEPTED 06 February 2023 PUBLISHED 09 March 2023

CITATION

Yang Y, Yan S, Yao N, Guo Y, Wang H, Sun M, Hu W, Li X, Wang L and Li B (2023) Effects of vitamin D supplementation on the regulation of blood lipid levels in prediabetic subjects: A meta-analysis. *Front. Nutr.* 10:983515. doi: 10.3389/fnut.2023.983515

COPYRIGHT

© 2023 Yang, Yan, Yao, Guo, Wang, Sun, Hu, Li, Wang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Effects of vitamin D supplementation on the regulation of blood lipid levels in prediabetic subjects: A meta-analysis

Yixue Yang¹, Shoumeng Yan², Nan Yao¹, Yinpei Guo¹, Han Wang¹, Mengzi Sun¹, Wenyu Hu¹, Xiaotong Li¹, Ling Wang¹ and Bo Li^{1*}

¹Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, China, ²School of Nursing, Jilin University, Changchun, Jilin, China

This meta-analysis aimed to systematically investigate whether vitamin D supplementation reduces blood lipid-total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), and triglyceride (TG)-levels in prediabetic individuals. Pubmed, Web of Science, Cochrane Library, Embase, CNKI, and WANFANG databases were searched for studies published before 13 February 2022 (including 13 February 2022). Five articles were included. The results showed that vitamin D intervention led to a significant reduction in TG compared with control or placebo treatment (-0.42 [-0.59, -0.25], P < 0.001). Subgroup analyses showed that this effect was particularly significant among the studies that included obese subjects (-0.46 [-0.65, -0.28], P < 0.001), the studies that also included men (not only women) (-0.56 [-0.78, -0.34], P < 0.001), and the studies with intervention durations longer than 1 year (-0.46 [-0.65, -0.28], P < 0.001). Both relatively low doses of 2,857 IU/day (-0.65 [-0.92, -0.38], P < 0.001) and relatively high doses of 8,571 IU/day (-0.28 [-0.54, -0.02] P = 0.04) of vitamin D supplementation reduced TG levels, and the effect was observed both in Northern Europe (-0.65 [-0.92, -0.38], P < 0.001) and Asian (-0.25 [-0.48, -0.03], P = 0.03) country subgroups. No significant effects on TC, HDL-C, and LDL-C were shown. In conclusion, vitamin D supplementation might beneficially affect TG levels in individuals with prediabetes. Particularly longer durations of treatment, more than 1 year, with doses that correct vitamin deficiency/insufficiency, can have a beneficial effect. This meta-analysis was registered at www.crd.york.ac.uk/prospero (CRD42020160780).

KEYWORDS

vitamin D, meta-analysis, prediabetes, cholesterol, LDL cholesterol, HDL cholesterol, triglycerides

1. Introduction

The global burden of diabetes mellitus cannot be ignored. In the last several decades, the prevalence of diabetes mellitus has extensively increased worldwide (1). It has been estimated that in 2011, there were approximately 366 million patients with diabetes and that the number is expected to reach 552 million by 2030 (2). Additionally, diabetes is associated with a high risk of cardiovascular diseases, mortality, and high economic costs related to the treatment and associated working disability (3, 4).

Diabetes can be preceded by prediabetes, and timely intervention during the prediabetic state is important for preventing the progression of diabetes (1, 5, 6). Prediabetes is defined as a state with a blood glucose level beyond the normal value but not reaching the diagnostic criteria for diabetes, including impaired fasting glucose (IFG, defined as fasting plasma glucose of 6.1–6.9 mmol/L or 5.6–6.9 mmol/L), impaired glucose tolerance (IGT, defined as 2h OGTT plasma glucose of 7.8–11.1 mmol/L), or glycated hemoglobin A1c (HbA1c) levels between 39 and 47 mmol/mol (7). Dyslipidemia is an important characteristic of both prediabetes and diabetes and may aggravate diabetic complications (8–11).

Vitamin D deficiency is another growing health concern in many parts of the world, affecting more than 50% of the general population worldwide (12). At the same time, it has been observed that people with lower 25(OH)D levels tend to have higher blood glucose (9), insulin resistance (10), and a higher risk of type 2 diabetes mellitus (T2DM) (11). In addition, some studies have shown that vitamin D supplementation may ameliorate dyslipidemia in subjects with T2DM (13, 14). Potential mechanisms included reduced intestinal cholesterol absorption, decreased low-density lipoprotein deposition in macrophages and foam cell formation, increased lipoprotein lipase gene expression in muscles and adipose tissue, etc. (15–17). However, there is still controversy over whether vitamin D supplementation can improve lipid levels in subjects with prediabetes since such studies are rare and more equivocal.

Therefore, we performed a meta-analysis evaluating the effect of vitamin D supplementation on blood lipid levels in subjects with prediabetes.

2. Materials and methods

2.1. Data sources and searches

We comprehensively searched the PubMed, Web of Science, Cochrane Library, Embase, CNKI, and WANFANG databases for all studies with human subjects in any language published before 13 February 2022 (including 13 February 2022) (Figure 1). We explored changes in serum total cholesterol (TC), lowdensity lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) levels before and after intervention with vitamin D supplementation in comparison with changes in blood lipids on a control treatment without vitamin D supplementation. The control treatment was defined as no supplementation, placebo supplementation, or another treatment without vitamin D supplementation that was also present in the vitamin D supplementation group (e.g., lifestyle intervention, calcium carbonate supplementation, and omega-3 fatty acid supplementation). Two investigators independently reviewed the literature, discussed the inconsistencies, and worked independently during the selection process, data collection process, and study risk of bias assessment (Figure 2).

2.2. Inclusion and exclusion criteria

The included studies met the following criteria. Subjects should meet the diagnostic criteria for prediabetes (International Diabetes Federation (IDF)/World Health Organization (WHO) from 2006: fasting plasma glucose value in the range of 6.1-6.9 mmol/L or 110-125 mg/dl, or 2h oral glucose tolerance test (OGTT) plasma glucose value in the range of 7.8-11.0 mmol/L or 140-200 mg/dl (18) and American Diabetes Association (ADA) from 2004: fasting plasma glucose value in the range of 5.6-6.9 mmol/L or 100-125 mg/dl, or 2h OGTT plasma glucose value in the range of 7.8-11.0 mmol/L or 140-200 mg/dl; or HbA1c in the range of 39-47 mmol/mol or 5.7-6.4% (19). We restricted included studies to prospective intervention studies; studies included at least one vitamin D intervention group and one control group receiving no vitamin D supplementation, with the only difference between the intervention group and control group being vitamin D intervention; studies included at least one of the blood lipid indicators (TC, LDL-C, HDL-C, or TG); studies provided quantitative data before and after vitamin D intervention or quantitative changes after vitamin D intervention compared with baseline data of blood lipid indicators.

Duplicate articles in databases, studies that did not meet the above inclusion criteria, animal experiments, *in vitro* studies, reviews, and conference papers were excluded.

2.3. Data extraction

We read all included articles and then abstracted the following data: primary authors, nationality, and publication year; average age, gender, BMI, region, and the number of participants in each group; vitamin D supplement dose and time; criteria for prediabetes definition; TC, LDL-C, HDL-C, and TG alterations in intervention groups and control groups. If the included original article had more than one intervention group or control group, we chose the most suitable group for further analysis.

2.4. Quality assessment

Two investigators independently assessed the risk of bias using RevMan 5.3, including selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias, which were classified into three levels as high, low, or unclear, along with discussion and negotiation with respect to inconsistency. The

Abbreviations: HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; SMD, standardized mean difference; CI, confidence interval; BMI, body mass index; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; FEM, fixed effect model; REM, random effect model; SD, standard deviation; PPARγ, peroxisome proliferator-activated receptor-gamma; C/EBPα, CCAAT enhancer binding protein-alpha; IDF, International Diabetes Federation; ADA, American Diabetes Association; WHO, World Health Organization; HbA1c, glycated hemoglobin A1c; T2DM, type 2 diabetes mellitus; PTH, parathyroid hormone; RAAS, renin-angiotensin-aldosterone system; SREBP1c, sterol regulatory element-binding protein 1c; LPL, lipoprotein lipase; AP2, adipocyte-binding protein 2.



judgment standards were established from Cochrane Handbook for Systematic Reviews of Interventions (20).

average changes in blood TC, LDL-C, HDL-C, and TG levels compared to baseline values (mean \pm SD) (SD: standard deviation). When the original studies did not provide changes in SD, the formula in the Cochrane handbook was used to calculate (20).

2.5. Statistical analysis

In this study, the RevMan 5.3 and Stata 12.0 software were used for statistical analysis. The average differences between the intervention group and the control group were calculated by the

$$SD_{change} = \sqrt{SD_{baseline}^2 + SD_{end}^2 - (2 \times R \times SD_{baseline} \times SD_{end})}$$

The correlation coefficient R of the equation was estimated using the baseline value, endpoint, and change values of blood



lipids from other studies with vitamin D supplementation. Finally, the estimated R-value of this study was 0.84. The 95% confidence interval (CI), interquartile range (IQR), and 5th and 95th percentiles could also be transformed into SD (20) (1–0.95/2 = 0.025, then the value x was found using the formula = tinv(1–0.95, N-1) in Excel, where N means the population of this group).

$$SD = [\sqrt{N} \times (95\%CI_{Upper \ limit} - 95\%CI_{Lower \ limit})] \div 2x$$
$$SD = IQR \div 1.35 = (95th \ percentiles - 5th \ percentiles) \div 3.29$$

The mean and SD of serum TC, LDL-C, HDL-C, and TG concentrations changes in the intervention group and the control group were compared by standardized mean difference (SMD). Cochran's Q-statistics and I^2 -statistics were used to evaluate the statistical heterogeneity in the meta-analysis. In a meta-analysis, the random effect model (REM) was used when data were heterogeneous, and the fixed effect model (FEM) was used when data were not heterogeneous (20), but model-using in subgroup analyses of TC, LDL-C, HDL-C, and TG remained consistent with

the total meta-analysis of TC, LDL-C, HDL-C, and TG separately. In this study, SMD and 95% CI of TC and HDL-C changes were measured by REM; SMD and 95% CI of LDL-C and TG changes were measured by FEM; and data were compared between the vitamin D group and the control group.

In the Q-test, a *p*-value of <0.05 was indicative of heterogeneity, and the I²-value was used to evaluate the degree of heterogeneity. Influence analysis and Egger's test were performed using the Stata software to determine the stability and possible sources of heterogeneity. Combining the opinions of two investigators, the RevMan software was used for risk assessment. In addition, subgroup analysis was conducted according to BMI [overweight defined as 23–24.9, obesity as 25 or over 25 in Indian studies (21); overweight defined as 25–29.9, obesity as 30 or over 30 in other studies (22)], region (Northern Europe and Asia), vitamin D supplement dose (relatively low dose, relatively medium dose, and relatively high dose; according to included studies, we have found that doses of included studies were 2,857 IU/day, 3,571 IU/day, and 8,571 IU/day, therefore, we defined 2,857 IU/day as relatively low

Yang et al.

TABLE 1 Basic information of included studies.

References	Region	Intervention Dose (IU/D)	Intervention Duration (Day)	Study participants Total (intervention	Sex [Female N (%),		Baseline BM	ll (kg/m ²)	Baseline	e age
				/control)	Intervention	Control	Intervention	Control	Intervention	Control
(A)										
Bhatt et al. (21)	India	8571 or 200 ^a	546	121 (61/60)	61 (100.0)/0 (0.0)	60 (100.0)/0 (0.0)	31.10 ± 6.20	28.80 ± 3.90	20-60	20-60
Dutta et al. (5)	India	8571 ^b	56	104 (55/49)	33 (60.0)/22 (40.0)	26 (53.1)/23 (46.9)	26.32 ± 4.52	26.83 ± 4.63	48.37 ± 10.47	47.40 ± 11.51
Dutta et al. (3)	IIIdia	2000 ^b	≥309	104 (33/49)	55 (00.0)/22 (40.0)	20 (33.1)/23 (40.9)	20.52 ± 4.52	20.03 ± 4.03	40.37 ± 10.47	47.40 ± 11.31
Jorde et al. (23)	Norway	2857	365-1825	227 (116/111)	43 (37.1)/73 (62.9)	39 (35.1)/72 (64.9)	30.10 ± 4.10	29.80 ± 4.40	62.30 ± 8.10	61.90 ± 9.20
Rajabi-Naeeni et al. (30)	Iran	3571	56	84 (42/42)	42 (100.0)/0 (0.0)	42 (100.0)/0 (0.0)	27.01 ± 2.91	27.28 ± 2.74	39.92 ± 6.04	41.85 ± 7.48
Misra et al. (31)	India	8571 or 200 ^a	720	65 (37/28)	37 (100.0)/0 (0.0)	28 (100.0)/0 (0.0)	_	-	48.10 ± 6.70	46.10 ± 8.10

BMI data are shown as mean ± SD; age data are shown as mean ± SD or age range; original doses were converted into doses per day and were rounded if they were not integers; 1 month was converted into 30 days. –Data were unavailable or could not be calculated. ^aIntervention dose; gave 60 000 IU/week for the first 8 weeks, adjusted doses every 24 weeks according to blood 25(OH)D levels, gave 60,000 IU/week for 8 weeks to subjects with vitamin D deficient, gave 200 IU/day to subjects with normal blood 25(OH)D level. ^bIntervention dose; 60,000 U/W for the first 8 weeks, then 60,000 U/M, subjects were followed up for at least 12 months. BMI, body mass index; SD, standard deviation.

References	TC change	(mmol/L)	LDL-C chang	ge (mmol/L)	HDL-C chang	e (mmol/L)	TG change (mmol/L)	
	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control
(B)								
Bhatt et al. (21)	-0.18 ± 0.60	0.26 ± 0.61	0.12 ± 0.49	0.07 ± 0.44	0.08 ± 0.16	0.03 ± 0.17	-0.10 ± 0.48	-0.01 ± 0.37
Dutta et al. (5)	_	-	-0.25 ± 0.46	-0.18 ± 0.36	-0.12 ± 0.15	-0.03 ± 0.16	-0.06 ± 0.40	0.09 ± 0.41
Jorde et al. (23)	-0.41 ± 0.59	-0.50 ± 0.59	-0.14 ± 0.52	-0.18 ± 0.52	0.09 ± 0.21	0.04 ± 0.21	-0.20 ± 0.43	0.10 ± 0.49
Rajabi-Naeeni et al. (30)	-0.27 ± 0.53	-0.11 ± 0.49	-0.27 ± 0.46	-0.11 ± 0.44	0.01 ± 0.16	-0.01 ± 0.13	0.04 ± 0.49	0.12 ± 0.39
Misra et al. (31)	-0.85 ± 0.66	-0.86 ± 0.87	_	_	_	_	_	_

Data are shown as mean \pm SD. – Data were unavailable or could not be calculated. HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation.

dose, 3,571 IU/day as relatively medium dose, and 8,571 IU/day as a relatively high dose in this meta-analysis), intervention time [short term defined as <365 days and long term defined as \geq 365 days according to some articles (6, 23–29)], sex (only female or and male), and criteria for prediabetes definition (according to IDF/WHO or ADA criteria).

3. Results

3.1. Literature search

A total of 14,734 citations were retrieved, and only 5 papers fully met the inclusion criteria (5, 21, 23, 30, 31). These five articles included a sample of 601 subjects, with 311 in the vitamin D intervention group and 290 in the control group. Basic characteristics and details are shown in Table 1. The duration of treatment in the included studies ranged \geq 56 days, and the dose of vitamin D ranged from 200 to 8,571 IU/day. In two studies, the control treatment involved only a placebo (23, 30); in the other two studies, placebo plus calcium carbonate supplementation (21, 31); and in one study, placebo plus calcium carbonate supplementation and lifestyle intervention (5) (note: also in the vitamin D intervention group, the same control treatments were applied).

As shown in Table 1, four studies were conducted in Asia and one in Northern Europe; one study excluded obese subjects (i.e., only normal weight and overweight subjects were included), three studies included obese subjects, and one did not provide BMI information. The experimental group in one study was supplemented with relatively low-dose vitamin D, one was supplemented with relatively medium-dose vitamin D, and three were supplemented with relatively high-dose vitamin D; one study carried out short-term interventions, and four carried out longterm interventions; three studies only had female subjects, and two had both male and female subjects; Four studies used ADA criteria for prediabetes; one used IDF/WHO criteria.

3.2. Risk of bias assessment

The risk of bias is shown in Figures 2A, B. Systematically speaking of this meta-analysis, the risks of random sequence generation bias and reporting bias in the included studies were very low; the risks of allocation concealment bias, attrition bias, and other biases were low; the risk of detection bias was relatively low; and the risk of performance bias was relatively high.

3.3. Meta-analysis

The differences in TG change (P < 0.001; Figure 3D, Table 2) between the intervention group and the control group were statistically significant. Compared to the control group, TG in the blood in the intervention group decreased more after vitamin D supplementation. But there were no significant differences in blood TC change (P = 0.33; Figure 3A, Table 2), blood LDL-C change (P = 0.73; Figure 3B, Table 2), or blood HDL-C change (P = 0.73; Figure 3B, Table 2), or b

3.4. Subgroup analysis results

Only in the subgroup of studies that included obese subjects (not only normal weight and overweight), vitamin D supplementation led to more reductions in TG levels compared to the control treatments (P < 0.001; Figure 4). The effect of vitamin D supplementation on TG levels was observed both in the subgroup of Asian countries (P = 0.03; Figure 5) and the subgroup of Northern European counties (P < 0.001; Figure 5), and both in the relatively high-dose subgroup (P = 0.04; Figure 6) and in the relatively low-dose subgroup (P < 0.001; Figure 6). Only in the long-term intervention subgroup (more than 1 year of vitamin D supplementation) (P < 0.001; Figure 7) and only in the subgroup with both female and male subjects included (not only females) (P < 0.001; Figure 8), the effect of vitamin D supplementation on TG levels was observed. Both in the IDF/WHO subgroup (P < 0.001; Figure 9) and the ADA subgroup (P = 0.03; Figure 9), vitamin D supplementation led to more reductions in TG levels compared to the control treatments. It was noteworthy to emphasize that studies with obese subjects included were all long-term interventions (more than 1 year of vitamin D supplementation), while the only study (30) with non-obese subjects included was at the same time a short-term intervention (only 56 days), and the vitamin D levels in that study were not corrected at the end of the study (they remained insufficient). Additionally, this short-term intervention study was the only study with a relatively medium dose included, where the effect was not observed (P = 0.41; Figures 4, 6, 7).

The effects on TC in obese, relatively high-dose, and longtime subgroups and on HDL-C in obese, relatively high-dose, Asian, long-time, female and male, and ADA subgroups showed heterogeneity (Table 3).

3.5. Influence analysis and Egger's test

The impact of every single article on heterogeneity was observed in Figure 10. The study by Jorde et al. (23) seemed different from the others in this meta-analysis of TC. In addition, according to Egger's test, there was no significant publication bias in any of the included articles for TC (P = 0.540), LDL-C (P = 0.213), HDL-C (P = 0.529), or TG (P = 0.096).

4. Discussion

The results of our meta-analysis showed that vitamin D supplementation could decrease circulating TG levels in subjects with prediabetes, especially in certain situations, but failed to confirm the effects on TC, HDL-C, and LDL-C levels.

Many studies have shown that low serum 25(OH)D concentration was associated with adverse lipid status (32), and some studies indicated that vitamin D supplementation could improve serum TC, TG, and LDL-C levels also in patients with T2DM (13, 14) and in subjects with metabolic syndrome (33).



TABLE 2 Results of meta-analysis in five included articles.

Index	Number of Studies	SMD [95%CI]	l ²
TC	4	-0.21 [-0.64,0.21]	81% [‡]
LDL-C	4	-0.03[-0.20, 0.14]	22%
HDL-C	4	0.03 [-0.34, 0.41]	78% ‡
TG	4	$-0.42~[-0.59,-0.25]^\dagger$	45%

 $^{^{\}dagger}P$ < 0.05 of the test for overall effect; $^{\ddagger}P$ < 0.05 of the test for heterogeneity. SMD, standardized mean difference; CI, confidence interval.

The effect of vitamin D supplementation on TG levels can be mediated through (1) increased calcium levels; (2) suppression of parathyroid hormone (PTH) secretion; (3) inhibition of lipolysis; (4) suppression of inflammation; (5) suppression of renin-angiotensin-aldosterone system (RAAS) activity; (6) its interaction with glucocorticoids and sex hormones; (7) upregulation of adiponectin; (8) improvement in insulin resistance and insulin levels; (9) its direct inhibition of the expression of nuclear factor sterol regulatory element-binding protein 1c (SREBP1c) involved in hepatic TG synthesis; (10) increased TG clearance by upregulation of lipoprotein lipase (LPL), neutral sphingomyelinases, PPAR γ , and adipocyte-binding protein 2 (AP2); or by (11) upregulation of mitochondrial oxidation (34–41).

Since adipose tissue can sequestrate and metabolize vitamin D and consequently lower its circulating and bioavailable levels for other metabolically active tissues involved in lipid metabolism (including muscle, liver, and pancreas) (42-45), we conducted an additional stratified analysis according to BMI categories. Our stratified analysis has shown that, particularly in the studies (5, 21, 23) that included obese subjects with prediabetes (not only normal weight and overweight subjects), the effect on TG levels was more marked compared with the study that excluded obese subjects (30). This result might be affected by the fact that in some of the studies that included obese subjects, men were also included (not only women). Our sex-subgroup analysis showed that the effect on TG was more marked in the mixed-sex studies (5, 23) than in the studies that included only women (21, 30) where the effect was not significant. Additionally, the durations of interventions in the studies (5, 21, 23) that also included obese subjects were over 1 year, while the duration of the treatment in the study that excluded obese subjects (30) was 8 weeks. Those factors can be significant confounders, which need to be taken into consideration when making conclusions. Nevertheless, there might be a more direct association. For example, obese subjects can have much higher TG levels compared with non-obese subjects, and therefore the effect can be more observable, especially during prolonged treatment. An additional explanation could be that obese subjects are more prone to vitamin D deficiency, while improvements in insulin resistance and related metabolic features can be observed after its correction. However, the later explanation failed to be confirmed in this study. In the study by Rajabi-Naeeni et al. (30) (where the effect on TG was not shown), the included normal weight and overweight subjects were with vitamin D insufficient status, in the study by Bhatt et al. (21) (where the effect was also not shown) the included overweight and obese subjects were with vitamin D deficient status, while in the studies by Dutta et al. (5) and Jorde et al. (23) (the ones which have found the significant effect on TG), they were with vitamin D insufficient status and no BMI restrictions. Therefore, the effect was neither associated with the baseline vitamin D status nor the BMI status, which is in agreement with a recent pooled metaanalysis (46). However, it is important to say that in the study by Bhatt et al. (21), the BMI-cut off for obesity was set at a much lower level (>25 kg/m²) according to Indian references, whereas in the other studies, it was set at the BMI-cut off for overweight. Finally, the effect cannot be explained by the rationale that vitamin D supplementation could affect body weight since not enough evidence exists on the effect of vitamin D on body weight reduction (42, 43, 47, 48), and no significant reductions in BMI were shown in the analyzed studies by vitamin D supplementation in comparison with the control treatments (5, 21, 23). Therefore, the finding of the more pronounced effect on TG in the studies which also included obese subjects was probably confounded by the influence of duration of treatment and/or possible gender differences in the response to supplementation (49).

As there are huge ethical/regional differences in vitamin D levels and responses to supplementation (50-56), we also conducted a region-subgroup analysis. The results showed that the effect on TG was not region-specific and was observed in both region-subgroups (Asia and Northern Europe). However, since this meta-analysis only included studies from India (three studies), Iran (one study), and Norway (one study), the results probably cannot

Α		В
Vitamin D Control Study or Subgroup Mean SD Total Mean SD Total Weight	Std. Mean Difference Std. Mean Difference IV, Random, 95% Cl IV, Random, 95% Cl	Vitamin D Control Std. Mean Difference Std. Mean Difference Study or Subgroup Mean SD Total Mean SD Total Weight IV, Fixed, 95% CI IV, Fixed, 95% CI
2.1.1 exclude obese	IV, Random, 95% CI IV, Random, 95% CI	Study of subgroup mean SU Total mean SU Total weight IV, Hxee, 95% CI IV, Hxee, 95% CI
Rajabi-Naeeni 2020 -0.27 0.53 42 -0.11 0.49 42 31.3%	-0.31 [-0.74, 0.12]	Rajabi-Naeeni 2020 -0.27 0.46 42 -0.11 0.44 42 15.5% -0.35 [-0.78, 0.08]
Subtotal (95% CI) 42 42 31.3% Heterogeneity: Not applicable	-0.31 [-0.74, 0.12]	Subtotal (95% CI) 42 42 15.5% -0.35 [-0.78, 0.08]
Test for overall effect: $Z = 1.41$ (P = 0.16)		Test for overall effect: Z = 1.60 (P = 0.11)
2.1.2 include obese		2.2.2 include obese
Bhatt 2020 -0.18 0.6 61 0.26 0.61 60 33.0% Jorde 2016 -0.41 0.59 116 -0.5 0.59 111 35.7%	-0.72 [-1.09, -0.35]	Bhatt 2020 0.12 0.49 61 0.07 0.44 60 22.6% 0.11 [0.25, 0.46]
Subtotal (95% Cl) 177 171 68.7%	-0.28 [-1.13, 0.58]	Jorde 2016 -0.14 0.52 116 -0.18 0.52 111 42.5% 0.0810.18.0.34
Heterogeneity: Tau ² = 0.36; Chi ² = 14.44, df = 1 (P = 0.0001); l ² = 93%		Subtotal (95% CI) 232 220 84.5% 0.03 [-0.16, 0.21]
Test for overall effect Z = 0.63 (P = 0.53)		Heterogeneity: Chi ^p = 1.30, df = 2 (P = 0.52); i ^p = 0% Test for overall effect: Z = 0.31 (P = 0.76)
Total (95% CI) 219 213 100.0%	-0.28 [-0.83, 0.27]	
Heterogeneity: Tau ² = 0.20; Chi ² = 14.93, df = 2 (P = 0.0006); l ² = 87%	-2 -1 0 1	Total (95% Cl) 274 262 100.0% -0.03 [-0.20, 0.14]
Test for overall effect: Z = 1.00 (P = 0.32) Test for subgroup differences: Chi ² = 0.01, df = 1 (P = 0.94), i ² = 0%	Vitamin D Control	Heterogeneity: Chi ^P = 3.84, df= 3 (P = 0.28); P= 22% Test for overall effect Z = 0.35 (P = 0.73) -2 -1 0 1
		Test for subgroup differences: Chi ^a = 2.54. df = 1 (P = 0.11). P = 60.6% Vitamin D Control
C		D
Vitamin D Control	Std. Mean Difference Std. Mean Difference	Vitamin D Control Std. Mean Difference Std. Mean Difference
Vitamin D Control Study or Subgroup Mean SD Total Mean SD Total Weight		
Vitamin D Control Study or Subgroup Mean SD Total Mean SD Total Weight 2.3.1 exclude obese Rajabi-Naeeni 2020 0.01 0.16 42 -0.01 0.13 42 2.9%	N, Random, 95% Cl N, Random, 95% Cl 0.14 (-0.29, 0.56)	Vitamin D Control Stat. Mean Difference Stat. Mean Difference Study of Subgroup Mean SD Total Mean SD Total Mean SD Total 2.4.1 exclude obese Fraid-Neem 1202 0.04 0.49 42 0.11%
Vitamin D Control Study or Subgroup Mean SD Total Mean SD Total Meight 2.3.1 exclude obese Rajabi-Naeeni 2020 0.01 0.16 42 -0.01 0.13 42 22.9% Subtrotal (95% CD) 42 22.9% 42 22.9% 42 22.9%	N, Random, 95% Cl N, Random, 95% Cl 0.14 (-0.29, 0.56)	Vitamin0 Control Study or Subgroup Mean SD Total Mean SD
Vitamin D Control Study or Subgroup Mean SD Total Mean SD Total Weight 2.3.1 exclude obese Rajabi-Naeeni 2020 0.01 0.16 42 -0.01 0.13 42 2.9%	N, Random, 95% Cl N, Random, 95% Cl 0.14 (-0.29, 0.56)	Vitamin D Control Stat. Mean Difference Stat. Mean Difference Study of Subgroup Mean SD Total Mean SD Total Mean SD Total 2.4.1 exclude obese Fraid-Neem 1202 0.04 0.49 42 0.11%
Vitamin D Control Study of Subgroup Mean SD Total Mean SD Total Mean 2.3.1 exclude obese Rajbal-Vickeeni (2020) 0.01 0.16 42 0.01 0.13 42 22.9% Subdral (9%) Subdral (9%) 42 24 22.9% 42 22.9% Heterogeneity: Not applicable 42 0.53) 23.2 10.12 42 22.9%	M, Random, 95% CI M, Random, 95% CI 0.14 (-0.29, 0.56) 0.14 (-0.29, 0.56)	Vitamin D Control Std. Mean Difference Std. Mean SD Std. Std. Std. Std. Std. Std. Std. Std.
Varamin D Control Study of Subgroup Mean SD Total Mean SD Total Vesiaht 2.3.1 exclude obese Rajbel-Maeen (2020) 0.01 0.16 42 -0.01 0.13 42 22.9% Subtradt (95% CI) 42 20.9% 42 22.9% Hetrogeneity. Not applicable 42 22.9% Testor overall effect Z= 0.62 (P= 0.53) 23.2 mcMute obese Bintit 2020 0.00 0.16 10.03 0.17 60 25.1%	M, Random, 95% C1 M, Random, 95% C1 0.14 [-0.29, 0.56] 0.14 [-0.29, 0.56] 0.30 [-0.06, 0.66] •	Vitamin D Control Std. Mean Difference Std. Mean Difference Std. Mean Difference 2.4.1 exclude obese Rajabi-Neem/ 2020 0.4 0.4 0.4 0.2 0.1 0.39 4.2 16.1% M. Fixed, 95% CI M. Fixed, 95% CI M. Fixed, 95% CI Rajabi-Neem/ 2020 0.4 0.4 0.4 2.0 1.2 0.39 4.2 16.1% -0.18 [-0.61, 0.25] Heitoropendix Not applicable Test for overall effect Z = 0.92 (P = 0.41) 2.4.2 16.1% -0.18 [-0.67, 0.15] - 2.4.2 include obese Bihati 2020 -0.1 0.48 61 -0.01 0.37 60 23.1% -0.21 [-0.57, 0.15] -
Varamin D Control Study of Subgroup Mean SD Total Mean SD Total Vesiaht 2.3.1 exclude obese Rajbel-Maeen (2020) 0.01 0.16 42 -0.01 0.13 42 22.9% Subtradt (95% CI) 42 20.9% 42 22.9% Hetrogeneity. Not applicable 42 22.9% Testor overall effect Z= 0.62 (P= 0.53) 23.2 mcMute obese Bintit 2020 0.00 0.16 10.03 0.17 60 25.1%	M, Random, 95% C1 M, Random, 95% C1 0.14 (-0.29, 0.56) 0.14 (-0.29, 0.56) 0.30 (-0.06, 0.66) -0.58 (-0.97, -0.18)	Vitamin D Control Std. Mean Difference Std. Mean SD Std. Std. Std. Std. Std. Std. Std. Std.
Vutamin D Control South or Subgroup Mean SD Total Mean SD Total Mean 2.3.1 exclude obese Rajob-Naeeni (2020 0.01 0.16 42 0.01 0.13 42 22.9% Subtrated (95% C) 4202 (2% - 0.53) 22.3% Meterogoneinky. Not applicable Feet for overall effect 2 = 0.62 (2% - 0.53) 2.3.2.3.include obese Enviro 2020 0.00 0.16 61 0.03 0.17 60 25.1% Dutta 2014 -012 0.16 55 -0.03 0.17 60 24.1% Jorde 2016 0.09 0.21 116 0.04 0.21 111 28.1% Subtrate (16% C) C32 22.22 77.7% 27.2% 77.7%	M, Random, 95% CI M, Random, 95% CI 0.14 (-0.29, 0.56) 0.14 (-0.29, 0.56) 0.30 (-0.06, 0.66) -0.56 (-0.37, 0.18) 0.24 (-0.02, 0.59)	Vitamin D Control Stat. Mean Difference Mc Red, 95% CI Mc
Study of Subgroup Mean D Control 23.1 exclude obese Fajab-Haeen (2020) 0.01 0.16 42 -0.01 0.13 42 22.9% Subtord (95% CI) 422 0.01 0.16 42 20.9% 42 22.9% Heterogeneik, Not applicable 23.2 (bc.164) 0.62 (c) = 0.53) 23.2 10.01 0.13 42 22.9% Faber Ageneik, Not applicable 20.62 (c) = 0.53) 23.2 10.01 0.13 42 22.9% Faber Ageneik, Not applicable 20.82 (c) = 0.53) 23.2 10.01 0.13 42 22.9% Data 2020 0.08 0.16 61 0.03 0.17 60 25.1% Dutta 2014 0.12 0.15 55 0.03 0.16 42 24.0% Jorde 2016 0.99 0.11 116 0.10 111 23.1% 111 23.1%	M, Random, 95% C1 M, Random, 95% C1 0.14 [-0.28, 0.56] 0.14 [-0.28, 0.56] 0.30 [-0.06, 0.66]	Vitamin D Control Stat. Mean Difference Stat. Mean Difference Stat. Mean Difference 2.4.1 exclude obese Stat. Stat. Stat. Mean Difference M. Fixed, 95% CI M. Fixed, 95% CI M. Fixed, 95% CI Rajabi-Neem/ 2020 0.40 4.2 0.12 0.39 4.2 16.1% -0.18 [-0.61, 0.25] Subtotal (95% CI 4.2 16.1% -0.18 [-0.61, 0.25] Heitoropenety Not applicable Test for overall effect Z = 0.92 (P = 0.41) 2 2.31% -0.21 [-0.57, 0.15] Image: Control on the control on t
Vutamin D Control Study of Subgroup Mean SD Total Weinht 2.3.1 exclude obese Rajab-Haeen (2020) 0.01 0.16 42 -0.01 0.13 42 22.9% Stat/stat (95% CI) 422 0.02 0.01 0.13 42 22.9% Heterogeneiky: Not applicable 7 6.53 2.2 Mean 5.00 42 2.9% Data 2014 0.02 0.06 0.16 1 0.03 0.17 60 25.1% Dutta 2014 0.12 0.15 55 0.03 0.16 42 2.0% Voide 2016 0.90 0.16 61 0.03 0.17 60 25.1% Narde 2016 0.90 0.21 116 0.04 21.11 28.1% Stat/stat (95% CI) 232 220 77.1% 148 24.0% 0.01); #= 15%	M. Random, 95% C1 M. Random, 95% C1 0.14 (-0.29, 0.56) 0.44 (-0.29, 0.56) 0.30 (+0.26, 0.56) -0.56 (+0.97, -0.16) 0.44 (-0.02, 0.57) 0.40 (-0.25, 0.50)	Vitamin D Control Std. Mean Difference Std. Mean Difference Std. Mean Difference 2.4.1 exclude obese Aman SD Total Mean SD Total Mean SD Total Weight M. Fixed, 95% CI M. Fixed, 95% CI M. Fixed, 95% CI Rajabi-Naemi 2020 0.40 0.42 0.12 0.39 42 16.1% -0.18 [-0.61, 0.25] Subtotal (95% CI 42 16.1% -0.18 [-0.61, 0.25] Heirocomesh; Not applicable Test for overall effect Z = 0.92 (P = 0.41) 2 2.1% -0.21 [-0.57, 0.15] Image: Control on the contr
Vutamin D Control Study or Subgroup Mean SD Total Weinht 2.3.1 exclude obese Rajab-Haeen (2020) 0.01 0.16 42 -0.01 0.13 42 22.9% Stat/ot all (95% C) 42 20.90 1.01 0.16 42 22.9% Heterogoneiky: Not applicable 7.05 42 22.9% 1.01 1.03 42 22.9% Data 2020 0.01 0.16 61 0.03 0.17 60 25.1% Data 2020 0.08 0.16 61 0.03 0.17 60 25.1% Data 2021 0.016 0.03 0.16 49 24.0% Jorde 2016 0.09 0.21 116 0.04 21.11 28.1% Stat/ot al (95% C) 232 220 2.01 1.11 28.1% 26.5% Total (95% C) 25.1% 26.2 100.0% 7.1% 1.15.2% 27.2 7.1% 1.16 20.69 20.1% 27.1	M. Random, 95% C1 M. Random, 95% C1 0.14 (-0.29, 0.56) 0.44 (-0.29, 0.56) 0.45 (-0.27, 0.	Vitamin D Control Std. Mean Difference Std. Mean Difference Std. Mean Difference 2.4.1 exclude obese 8.1.0 man SD Total Weight M. Fixed, 95% CI M. Fixed, 95% CI Rajabi-Naemi 2020 0.4.0 0.4.2 0.1.2 0.3.9 4.2 16.1% -0.16 [5.6.1, 0.25] Heitoropender, Not applicable Test for overall effect Z = 0.82 (P = 0.41) 2.4.2 16.1% -0.18 [-0.67, 0.15] Dutta 2014 -0.01 0.4 6.0 23.1% -0.21 [-0.57, 0.15] Dutta 2014 -0.02 0.4 1.0 1.0 1.1 1.4.3% -0.65 [-0.92, -0.02] Joinde 2016 -0.2 0.3 1.0 1.1 1.3.3% -0.65 [-0.92, -0.03] Statotal (95% CI) 222 220 83.9% -0.45 [-0.65, -0.28] Image: Chine 2.4.05 (# 2 (P = 0.10)) Statotal (95% CI) 274 262 10.0% -0.42 [-0.59, -0.25] Image: Chine 2.4.3 (P = 0.10), P = 45%
Study or Subgroup Mean SD Control 23.1 exclude obsec Rojab-Haeen (2020) 0.01 0.16 42 0.01 0.13 42 22.9% Statif and (25% C) 0.01 0.16 42 0.01 0.13 42 22.9% Heterogeneity- Not applic able 76.65 0.02 0.01 0.13 42 22.9% Statif and (25% C) 0.00 0.16 61 0.03 0.17 60 51 Statif and (25% C) 0.00 0.16 61 0.03 0.17 60 51 Statif and (25% C) 0.00 0.16 61 0.03 0.17 60 51 Statif and (25% C) 0.00 0.16 61 0.02 11 2.02 7.71% Statif and (25% C) 0.00 0.16 61 0.02 11 2.02 7.71% Statif and (25% C) 0.02 116 0.04 0.21 111 2.02 7.71% Statif and (25% C)	M. Random, 95% C1 M. Random, 95% C1 0.14 (-0.29, 0.56) 0.44 (-0.29, 0.56) 0.30 (+0.65, 0.66) -0.55 (+0.97, -0.18) 0.34 (+0.50, 0.50) 0.00 (+0.50, 0.50)	Vitamin D Control Stat. Mean Difference Stat. Mean Differenc<

FIGURE 4

Subgroup analysis by BMI. (A) TC, (B) LDL–C, (C) HDL–C, and (D) TG. BMI, body mass index; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride.



be extrapolated to other regions or ethnicity subgroups, and relative trials in more regions are needed.

We conducted a subgroup analysis of intervention dose and time according to some studies with the idea that insufficient vitamin D dose and intervention time might affect the research results (24). The results showed that in our relatively low-dose (2,857 IU/day) and relatively high-dose (8,571 IU/day) subgroups, vitamin D intervention provided significantly larger reductions in TG, but such an effect was not observed in the relatively medium-dose subgroup. However, the relatively medium-dose group only included one study by Rajabi-Naeeni et al. (30), which was at the same time the only study in the short-duration group. Changes in glucose tolerance and blood lipid levels are usually a slow and gradual process, and previous research suggests that interventions lasting only a few months may be a too short time frame to evaluate the benefits of vitamin D, implying that even 1 year is not enough for a long-term intervention (6, 24, 25, 33). In our analysis, significantly larger reductions in TG levels in the

								в								
udy or Subgroup	Vitamin D Mean SD To	Cont tal Mean			Std. Mean Difference IV, Random, 95% CI		n Difference om, 95% Cl		Study or Subgroup	Vitamin D Mean SD To		ntrol SD Total		Std. Mean Difference IV, Fixed, 95% CI		Mean Difference 7, Fixed, 95% Cl
1.1 low dose orde 2016 ubtotal (95% CI) eterogeneity: Not ap est for overall effect:	oplicable	16		28.3% 28.3%	0.15 [-0.11, 0.41] 0.15 [-0.11, 0.41]		•	Jo Si H	2.2.1 low dose forde 2016 Subtotal (95% CI) Heterogeneity: Not ap Fest for overall effect:	plicable	16 -0.18 16		42.5% 42.5%	0.08 [-0.18, 0.34] 0.08 [-0.18, 0.34]		ŧ
1.2 medium dose ajabi-Naeeni 2020 abtotal (95% CI) eterogeneity: Not ap est for overall effect		42 -0.11 0. 42		23.9% 23.9%	-0.31 [-0.74, 0.12] - 0.31 [-0.74, 0.12]	4	-	R Si H	2.22 medium dose Rajabi-Naeeni 2020 Subtotal (95% CI) Heterogeneity: Not ap Test for overall effect:	plicable	42 -0.11 42		15.5% 15.5%	-0.35 [-0.78, 0.08] - 0.35 [-0.78, 0.08]	-	•
1.3 high dose hatt 2020 isra 2021 ubtotal (95% CI) eterogeneity: Tau ² = est for overall effect:	-0.85 0.66		87 28 88	22.3% 47.8%	-0.72 [-1.09, -0.35] 0.01 [-0.48, 0.50] - 0.37 [-1.09, 0.35]	-	-	BI D SI H	2.2.3 high dose Shatt 2020 Outta 2014 Subtotal (95% CI) Heterogeneity: Chi ² = Test for overall effect	-0.25 0.46 1 1.04, df = 1 (P = 0.3	61 0.07 55 -0.18 16 1); I ² = 4%	0.36 49	22.6% 19.4% 42.0 %	0.11 [-0.25, 0.46] -0.17 [-0.55, 0.22] -0.02 [-0.28, 0.24]		•
otal (95% Cl) ieterogeneity: Tau² = est for overall effect:	0.15; Chi ² = 15.41, Z = 0.98 (P = 0.33)		01); I [#] = 8		-0.21 [-0.64, 0.21]	-2 -1 Vitamin E	0 1	2 H	otal (95% CI) leterogeneity: Chi² = est for overall effect:	3.84, df = 3 (P = 0.2 Z = 0.35 (P = 0.73)			100.0%	-0.03 [-0.20, 0.14]	-1 -1 -2 -1 Vita	min D Control
est for subaroup dif	ferences: Chi ⁴ = 4.3	4. df = 2 (P = (.11), I*=:	53.9%				T	est for subaroup diff	erences: Chi* = 2.8	U. (11 = 2 (1° =	0.25).1*=	10.370			
						04.8-		D						Std Mean Difference		Hann Difference
Study or Subgroup	Vitamin D	Cont	rol		Std. Mean Difference IV, Randorn, 95% Cl		n Difference Iom, 95% Cl	D	Study or Subgroup	Vitamin D Mean SD To	Co	ntrol		Std. Mean Difference IV, Fixed, 95% Cl		Mean Difference 7, Fixed, 95% Cl
Study or Subgroup 3.3.1 low dose lorde 2016 Subtotal (95% CI) Heterogeneity: Not ap	Vitamin D <u>Mean SD To</u> 0.09 0.21 1 1 oplicable	Com t <u>al Mean :</u> 16 0.04 0. 16	rol D Total 21 111	Weight			n Difference	D 3 	•	Vitamin D <u>Mean SD To</u> -0.2 0.43 1 plicable	Co tal Mean 16 0.1 16	ntrol SD Tota 0.49 111	Weight		P	
Fest for subaroup diff Study of Subgroup 3.3.1 low dose lorde 2016 Subtotal (95% CI) Heterogeneity. Not ap Test for overall effect 3.2.2 medium dose Alabi-Naeen / 2020 Subtotal (95% CI) Heterogeneity. Not ap Test for overall effect.	Vitamin D <u>Mean SD To</u> 0.09 0.21 1 1 pplicable Z = 1.78 (P = 0.07) 0.01 0.16 oplicable	Com tal Mean : 16 0.04 0. 16 42 -0.01 0. 42	rol 21 111 111 111	Weight 28.1%	IV, Random, 95% Cl 0.24 [-0.02, 0.50]		n Difference	D 33 1 s н т т 3 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	Study or Subgroup 3.4.1 low dose Jorde 2016 Subtotal (95% CI) Heterogeneity: Not ap	Vitamin D <u>Mean SD To</u> -0.2 0.43 1 1 plicable Z=4.77 (P < 0.000 0.04 0.49 plicable	Co tal Mean 16 0.1 16 101) 42 0.12 42	ntrol <u>SD Tota</u> 0.49 111 111 0.39 42	Weight 41.3%	IV, Fixed, 95% Cl	P	/, Fixed, 95% Cl
Study or Subgroup 3.3.1 low dose Jorde 2016 Subtotal (95% CI) Heterogeneity: Not ag Test for overall effect: 3.3.2 medium dose Rajabi-Naeeni 2020 Subtotal (95% CI) Heterogeneity: Not ag	Vitamin D Mean SD To 0.09 0.21 1 pplicable Z = 1.78 (P = 0.07) 0.01 0.16 pplicable 0.08 0.16 -0.12 0.15 1 0.05; Ch ² = 10.46,	Cont tal Mean : 16 0.04 0. 16 42 -0.01 0. 42 -0.01 0. 42 -0.03 0. 55 -0.03 0. 16	rol 21 111 111 13 42 42 17 60 16 49 109	Weight 28.1% 28.1% 22.9% 22.9% 22.9% 25.1% 24.0% 49.1%	N, Random, 95% Cl 0.24 [-0.02, 0.50] 0.24 [-0.02, 0.50] 0.14 [-0.29, 0.56]		n Difference	D 3 3 5 5 1 5 7 7 7 7 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8	Study or Subgroup 3.4.1 low dose Jorde 2016 Subtotal (95% CI) Heterogeneity: Not ag Test for overall effect: 3.4.2 medium dose Rajabi-Naeeni 2020 Subtotal (95% CI) Heterogeneity: Not ag	Vitamin D Mean SD To -0.2 0.43 1 plicable Z = 4.77 (P < 0.000 0.04 0.49 plicable Z = 0.82 (P = 0.41) -0.1 0.48 -0.06 0.4 0.35, df = 1 (P = 0.1)	Ctal Mean 16 0.1 16 0.1 16 101) 42 0.12 42 61 -0.01 55 0.09 16 16 55; (P = 0%	ntrol <u>SD Tota</u> 0.49 111 111 0.39 42 42 0.37 60	Weight 41.3% 41.3% 16.1% 16.1% 23.1% 19.5%	V, Fixed, 95% CI -0.65 [-0.92, -0.38] -0.65 [-0.92, -0.38] -0.18 [-0.61, 0.25]		/, Fixed, 95% Cl

FIGURE 6

Subgroup analysis by intervention dose. (A) TC, (B) LDL-C, (C) HDL-C, and (D) TG. TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride.

idy or Subgroup	Vitamin D Mean SD To	Control otal Mean SD	Total Weight	Std. Mean Difference IV, Random, 95% Cl	Std. Mean Difference IV, Random, 95% CI	Vitamin D Control Std. Mean Difference Std. Mean Difference Study or Subgroup Mean SD Total Mean SD Total Weight IV, Fixed, 95% CI IV, Fixed, 95% CI
.1 short jabi-Naeeni 2020 btotal (95% CI) terogeneity: Not ap st for overall effect .	plicable	42 -0.11 0.49 42	42 23.9% 42 23.9%	-0.31 [-0.74, 0.12] -0.31 [-0.74, 0.12]	•	5.2.1 short F.2.1
.2 long att 2020 ide 2016 sra 2021 btotal (95% CI) terogeneity: Tau ² = st for overall effect.	-0.41 0.59 -0.85 0.66 0.22; Chi ^a = 14.76		60 25.6% 111 28.3% 28 22.3% 199 76.1% 0); P = 86%	-0.72 [-1.09, -0.35] 0.15 [-0.11, 0.41] 0.01 [-0.48, 0.50] -0.18 [-0.76, 0.39]		5.22 long Bhat 2020 0.12 0.48 61 0.07 0.44 60 22.6% 0.11 [-0.25, 0.46] Dufta 2014 -0.22 0.46 55 -0.18 0.36 49 104.4% -0.17 [-0.55, 0.22] Jone 2016 -0.14 0.52 116 -0.18 0.52 111 4.25% 0.08 [-0.18, 0.34] Subtotal (95% CI) -2322 220 84.5% 0.03 [-0.16, 0.21] Helerogeneity: Ch [™] = 1.30, d [™] = 2 (P = 0.52); P = 0% Test for overall effect Z = 0.31 (P = 0.75).
al (95% CI) terogeneity: Tau² = st for overall effect : st for suboroup diffe	0.15; Chi ² = 15.41 Z = 0.98 (P = 0.33			-0.21 [-0.64, 0.21] _	-2 -1 0 1 2 Vitamin D Control	Total (95% CI) 274 262 100.0% -0.03 [-0.20, 0.14] Heterogenetity: Chill* = 3.84, df = 3 (P = 0.28); P = 22% -0.03 [-0.20, 0.14] -2 -1 0 1 2 Test for overall effect 22 = 0.36 (P = 0.73); -2.05 (P = 0.73); P = 0.05 (P = 0.73); -2 -1 0 1 2 Test for solution up differences: Chil* = 2.54, df = 1 (P = 0.11); P = 60.6% Vitamin D Control
						D
idy or Subgroup	Vitamin D Mean SD T	Control otal Mean SD	Total Weigh	Std. Mean Difference IV, Random, 95% Cl	Std. Mean Difference IV, Random, 95% Cl	Vitamin D Control Std. Mean Difference Std. Mean Difference Study or Subgroup Mean SD Total Mean SD Total Vitamin
I .1 short ijabi-Naeeni 2020 btotal (95% CI) terogeneity: Not ap st for overall effect	plicable	42 -0.01 0.13 42	42 22.9% 42 22.9%		+	5.4.1 short Rajabi-Naeeni 2020 0.04 0.49 42 0.12 0.39 42 16.1% -0.18 [-0.61, 0.25] Subtotal (195% Cf) 42 42 16.1% -0.18 [-0.61, 0.25] Heterogeneity: Not applicable Test for overall affect 2 = 0.82 (P = 0.41)
t.2 long att 2020 tta 2014 de 2016 btotal (95% CI) terogeneity: Tau ² = st for overall effect	0.09 0.21 0.17; Chi ² = 13.58		220 77.1%	0.30 [-0.06, 0.66] -0.58 [-0.97, -0.18] 0.24 [-0.02, 0.50] 0.00 [-0.50, 0.50]		5.4.2 long Bhat 2020 -0.1 0.48 61 -0.01 0.37 60 23.1% -0.21 [-0.57, 0.15] Dufta 2014 -0.06 0.4 55 0.09 0.41 49 19.5% -0.37 [-0.76, 0.02] Jone 2016 -0.2 0.43 116 0.1 0.49 111 41.3% -0.05 [-0.92, -0.38] Subtotal (5% C) -0.2 0.42 148 0.1 0.49 111 41.3% -0.05 [-0.92, -0.38] Subtotal (5% C) -0.2 0.42 148 0.1 0.49 111 41.3% -0.05 [-0.92, -0.38] Heterogenetity: Ch ²⁺ = 4.05, dr = 2 (P = 0.13); P = 51% Test for overall enet 22 = 4.84 (P = 0.0001)
tal (95% Cl) terogeneity: Tau² =	0.11; Chi ² = 13.65 Z = 0.18 (P = 0.86			0.03 [-0.34, 0.41]	-2 -1 0 1 2 Vitamin D Control	Tetal (05% CI) 274 262 190.0% -0.42 [-0.59, -0.25] Heateropenety: ChiP = 5.47, dF = 2 (0 = 0.10, P = 45%) -0.12 -2.10 -1.00 Test for overall effect Z = 4.76 (P < 0.0001)

intervention group had been observed only in the long-duration subgroup but not in the short-duration subgroup. Additionally, the vitamin D levels in the short-duration subgroup of the study (30) did not change to achieve vitamin D sufficiency after only 8 weeks of treatment. This implied that the relatively medium-dose group in our analysis was probably affected by the short duration of the study by Rajabi-Naeeni et al. (30). This is in agreement with a recent meta-analysis in subjects with metabolic syndrome, where the effects on TG levels were not shown in studies lasting <1 year (33). More short-term interventions are needed for further verification. Additionally, lower vitamin D doses than 2,857 IU/day or higher doses than 8,571 IU/day need to be tested in the future.

	В			
Experimental Control Std. Mean Diffe Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random,	ference Std. Mean Difference	Experimental Control up Mean SD Total Mean SD Total Weig	Std. Mean Difference Std. Mean Diffe ht IV, Fixed, 95% CI IV, Fixed, 95%	
6.1.1 entry female Bhat 2020 -0.18 0.6 61 0.26 0.61 0.25 5%, -0.72 [+1.0] Wisra 2021 -0.85 0.66 37 -0.86 0.87 28 22.3%, 0.01 [+0.4] Rajabi-Naeeni 2020 -0.27 0.53 42 -0.11 0.49 42 23.9%, -0.31 [+0.7] Subtradie (95%) 0.01 -0.4 1.0 71.7%, -0.36 [0.47] -0.36 [0.47] Heterogenethy: Tau*= 0.09, Chi*= 5.83, of = 2 (*= 0.05), i*= 65% Testfor overall effect 2 = 1.68 (*= 0.05) -0.66%	48, 0.50] Rajabi-Naeeni 20 74, 0.12] Subtotal (95% Cl) 79, 0.06] Heterogeneity. Cl	0.12 0.49 61 0.07 0.44 60 22.6 20 -0.27 0.46 42 -0.11 0.44 42 15.5	% -0.35 [-0.78, 0.08]	
s.1.2 female and male lorde 2016 -0.41 0.59 116 -0.5 0.59 111 28.3% 0.15 [-0.1 statotal (95% 0) 116 111 28.3% 0.15 [-0.1 relation consult direct 2 = 1.1.4 (P = 0.25)	11, 0.41] Subtotal (95% CI) Heterogeneity: CI	-0.25 0.46 55 -0.18 0.36 49 19.4 -0.14 0.52 116 -0.18 0.52 111 42.5	% 0.08 [-0.18, 0.34]	
Total (95% CI) 256 241 100.0% -0.21 [-0.6 Heterogeneth: Tau" = 0.15; Chil [®] = 15.41, cfr = 3 (P = 0.01); P = 91% Test for overall effect Z = 0.98 (P = 0.021); P = 0.04); P = 76.0%	-2 -1 0 1 2 Heterogeneity: Ch Test for overall ef	$\begin{array}{ccc} 274 & 262 & 100.6\\ \mu^{\mu}=3.84, df=3 \ (P=0.28); \ \mu=22\%\\ ect. Z=0.35 \ (P=0.73)\\ differences: ChiP=0.20. \ df=1 \ (P=0.65), \ \mu=0\%\\ \end{array}$	% -0.03 [-0.20, 0.14]	1 1 1 2
Experimental Control Std. Mean Diffe	erence Std. Mean Difference	Experimental Control	Std. Mean Difference Std. Mean Diffe	rence
Study or Subury output Mean SD Total Weinht M, Bandom, SJ. 3.51 den/ female 0.08 0.16 61 0.03 0.17 60 2.5.% 0.30 (-0.0 Shatt 2020 0.08 0.16 61 0.03 0.17 60 2.5.% 0.30 (-0.0 Shatt 2020 0.01 0.16 42 -0.01 0.13 42 2.2.9% 0.14 (-0.2 Shattoal (95%) 0.00, Ch ² 0.01 0.16 42 -0.01 0.24 4.0.4% Jakabi-Nateri 2020 0.00, Ch ² 0.03 16.0 103 102 48.0% 0.23 16.0 Heterogenethy, Tau ² 0.00, Ch ² 0.04 (-0.56), P = 0% 50.01 <td>3/25% CI V. Random, 95% CI Stutive of Subtraction 0,0.060 </td> <td>-0.1 0.48 61 -0.01 0.37 60 23.1</td> <td>% -0.21 [-0.57, 0.15] % -0.18 [-0.61, 0.25]</td> <td><u>5 CI</u></td>	3/25% CI V. Random, 95% CI Stutive of Subtraction 0,0.060	-0.1 0.48 61 -0.01 0.37 60 23.1	% -0.21 [-0.57, 0.15] % -0.18 [-0.61, 0.25]	<u>5 CI</u>
3.22 formale and male value 3014 - 0.12 0.15 55 -0.03 0.16 40 24.0%, -0.5914.0 30 orde 2016 0.08 0.21 116 0.04 0.21 111 38.1% 0.2414.0 abortod (95% C) 171 160 52.0%, -0.1614.0 leterogenety, Tau* 0.30; Chi* 11.4.3, df= 1 (P = 0.007); P = 91%, estforwend letter 2 = 0.38 (P = 0.70).	02, 0.50] Jorde 2016 55, 0.64] Subtotal (95% Cl) Heterogeneity: Cf	-0.06 0.4 55 0.09 0.41 49 19.5 -0.2 0.43 116 0.1 0.49 111 41.3	% -0.65 [-0.92, -0.38]	
	34, 0.41) Total (95% CI)	274 262 100.0	% -0.42 [-0.59, -0.25] ◆	

FIGURE 8

Subgroup analysis by sex. (A) TC, (B) LDL-C, (C), HDL-C, and (D) TG. TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride.



Association, which work heatth organization, criteria of IDF7 who non-zook, lasting plasma glucose values in the range of .1-0.5 mmol/L or 140–200 mg/dl; Criteria of ADA from 2004: fasting plasma glucose value in the range of .5-6.9 mmol/L or 100-125 mg/dl, or 2 h OGTT plasma glucose value in the range of .8-1.0 mmol/L or 140-200 mg/dl; Criteria of ADA from 2004: fasting plasma glucose value in the range of .5-6.9 mmol/L or 100-125 mg/dl, or 2 h OGTT plasma glucose value in the range of .7.8-11.0 mmol/L or 140-200 mg/dl; or HbA1c in the range of 39-47 mmol/mol or 5.7-6.4%.

We have also conducted subgroup analyses of the criteria for prediabetes. The results showed that the effect on TG was probably not affected by different criteria for prediabetes since it was observed in both criteria subgroups (IDF/WHO and ADA).

Our heterogeneity might come from studies with different study designs (different control interventions, doses, durations,

different inclusion criteria, baseline vitamin D status and corrections achieved, BMI, sex, and ethnicity of the subjects included). On the one hand, the significant heterogeneity disappeared after region, sex, and criteria for prediabetes subgroup analysis of TC, showing that region, gender, or criteria for prediabetes could affect the heterogeneity of our meta-analysis

TABLE 3 Results of subgroup meta-analysis.

	Index	BMI Su	bgroup		Dose Subgroup		Region S	ubgroup
		Exclude Obese	Include Obese	Low Dose	Medium Dose	High Dose	Northern Europe	Asia
(A)								
Number of Studies	TC	1	2	1	1	2	1	3
	LDL-C	1	3	1	1	2	1	3
	HDL-C	1	3	1	1	2	1	3
	TG	1	3	1	1	2	1	3
SMD	TC	-0.31 [-0.74, 0.12]	-0.28 [-1.13, 0.58]	0.15 [-0.11, 0.41]	-0.31 [-0.74, 0.12]	-0.37 [-1.09, 0.35]	0.15 [-0.11, 0.41]	-0.36 [-0.79, 0.06]
[95%CI]	LDL-C	-0.35 [-0.78, 0.08]	0.03 [-0.16, 0.21]	0.08 [-0.18, 0.34]	-0.35 [-0.78, 0.08]	-0.02 [-0.28, 0.24]	0.08 [-0.18, 0.34]	-0.11 [-0.33, 0.11]
	HDL-C	0.14 [-0.29, 0.56]	0.00 [-0.50, 0.50]	0.24 [-0.02, 0.50]	0.14 [-0.29, 0.56]	-0.13 [-0.99, 0.73]	0.24 [-0.02, 0.50]	-0.05 [-0.58, 0.49]
	TG	-0.18 [-0.61, 0.25]	-0.46 [-0.65, -0.28] [†]	-0.65 [-0.92 , -0.38] [†]	-0.18 [-0.61, 0.25]	-0.28 [-0.54, -0.02] [†]	-0.65 [-0.92, -0.38] [†]	-0.25 [-0.48, -0.03] [†]
I ²	TC	-	93 %‡	-	-	82% [‡]	-	66%
	LDL-C	-	0%	-	-	4%	-	26%
	HDL-C	-	85% [‡]	-	_	90 % [‡]	-	82% [‡]
	TG	-	51%	-	-	0%	-	0%

Sex subgroup

Female and male

1

2

2

2

0.15 [-0.11, 0.41]

0.00 [-0.22, 0.22]

-0.16 [-0.95, 0.64]

-0.56 [-0.78, -0.34][†]

_

5%

91%‡

27%

Only female

3

2

2

2

-0.36 [-0.79, 0.06]

-0.08[-0.35, 0.20]

0.23 [-0.04, 0.51]

-0.20[-0.47, 0.08]

66%

61%

0%

0%

Prediabetes criteria subgroup

3

3

3

3

-0.36 [-0.79, 0.06]

-0.11[-0.33, 0.11]

-0.05 [-0.58, 0.49]

-0.25 [-0.48, -0.03][†]

66%

26%

82%[‡]

0%

IDF/WHO

1

1

1

1

0.15 [-0.11, 0.41]

0.08 [-0.18, 0.34]

0.24 [-0.02, 0.50]

-0.65 [-0.92, -0.38][†]

_

_

_

_

Duration subgroup

3

3

3

3

-0.18 [-0.76, 0.39]

0.03 [-0.16, 0.21]

0.00 [-0.50, 0.50]

 $-0.46 \ [-0.65, -0.28]^{\dagger}$

86%‡

0%

85%‡

51%

frontiersin.org

Frontiers in Nutrition

		Short
(B)		
Number of Studies	TC	1
	LDL-C	1
	HDL-C	1
	TG	1
SMD	TC	-0.31 [-0.74, 0.12]
[95%CI]	LDL-C	-0.35 [-0.78, 0.08]
	HDL-C	0.14 [-0.29, 0.56]
	TG	-0.18 [-0.61, 0.25]
I^2	ТС	-
	LDL-C	-
	HDL-C	-
	TG	_

[†]P < 0.05 of the test for overall effect; [‡]P < 0.05 of the test for heterogeneity. BMI, body mass index; SMD, standardized mean difference; CI, confidence interval. BMI definition: in Indian studies, overweight = 23–24.9, obesity≥25; in other studies, overweight = 25–29.9, obesity≥30. Dose definition: relatively low-dose = 2,857 IU/day; relatively medium dose = 3,571 IU/day; relatively high dose = 8,571 IU/day. Duration definition: short-term <365 days; long-term≥365 days. Bold values: P < 0.05.



of TC. On the other hand, Figure 10 shows that the included article of Jorde et al. (23) was quite different from the others in this meta-analysis of TC. In the present study, in the subgroups with a North European population and relatively low dose and IDF/WHO prediabetic inclusion criteria, only the study of Jorde et al. (23) was included while regarding sex subgroups, only this study had a higher percentage of male participants. This suggested that the heterogeneity of this meta-analysis might come from the region, intervention dose, criteria of prediabetes, and sex of participants in the article by Jorde et al. (23). Besides, although it was not observed in Figure 10, the article by Rajabi-Naeeni et al. (30) was exceptional as well, with a relatively medium dose, a short duration, and the exclusion of obese subjects. Therefore, significant heterogeneity might also come from BMI, intervention dose, and intervention duration of the article by Rajabi-Naeeni et al. (30).

To make our analysis an all-around study as far as possible, we restricted our selection to prospective intervention trials based on the Cochrane Handbook for Systematic Reviews of Interventions and relative references (20, 57). Limitations of this meta-analysis were that there were not many studies (especially with normal BMI, more other regions, lower vitamin D doses than 2,857 IU/day and higher doses than 8,571 IU/day, and a low intervention

duration of vitamin D supplementation) that could be included in this meta-analysis. More studies are needed in the future. Several included studies did not state clearly if they collected blood lipid data when participants were fasting, and only few of the included studies controlled for the usage of lipid lowering medications in the study by Bhatt et al. (21), no information on lipid-lowering drugs usage was provided; in the study by Dutta et al. (5), participants using metformin, fever/active oral hypoglycaemic agents, oral contraceptive pills, steroids, and anti-epileptics were excluded; in the study by Jorde et al. (23), participants with use of statins were included, but there was no significant difference in use of statins between groups and those who changed their use of statins during the course of study, were excluded; in the study by Misra et al. (31), participants on medications within last 1 month which could potentially influence insulin secretion, insulin sensitivity, vitamin D, or calcium metabolism, including metformin, thiazolidinediones, steroids, and calcitonin were excluded; and in the study by Rajabi-Naeeni et al. (30), participants using herbal or chemical medications affecting lipids were excluded). Besides, there was significant heterogeneity in the studies included, related to different durations and doses of treatment, different BMI and gender of the subjects included, different regions and ethnic populations, different criteria for prediabetes, different control interventions, baseline vitamin D status, and corrections achieved.

However, despite all these limitations, our results may provide a basis for the implementation of regular assessment of vitamin D status among patients with prediabetes and consecutive supplementation in vitamin D deficient/insufficient patients to prevent an increase in blood lipids.

5. Conclusion

Vitamin D supplementation might beneficially affect TG levels in individuals with prediabetes. Particularly longer durations of treatment, more than 1 year, with doses that correct vitamin deficiency/insufficiency, can have a beneficial effect. Considering that there were not many studies that could be included in this meta-analysis, more studies are needed in the future.

Author contributions

YY and SY designed the study and analyzed the data. YY drafted the first manuscript and conducted the visualization. NY, YG, HW, MS, WH, XL, and LW validated the results. YY, SY, and BL participated in amending the manuscript. All authors contributed to the article and approved the submitted version.

Funding

Our research was supported by the National Natural Science Foundation of China (No. 81973129).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Gu D, Reynolds K, Duan X, Xin X, Chen J, Wu X, et al. Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). *Diabetologia*. (2003) 46:1190–8. doi: 10.1007/s00125-003-1167-8

2. Whiting DR, Guariguata L, Weil C, Shaw J, IDF. diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. *Diabetes Res Clin Pract.* (2011) 94:311–21. doi: 10.1016/j.diabres.2011.10.029

3. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med.* (1998) 339:229–34. doi: 10.1056/NEJM199807233390404

4. Sarwar N, Gao P, Seshasai SR. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet.* (2010) 375:2215–22. doi: 10.1016/S0140-6736(10)60484-9

5. Dutta D, Mondal SA, Choudhuri S, Maisnam I, Reza AH, Bhattacharya B, et al. Vitamin-D supplementation in prediabetes reduced progression to type 2 diabetes and was associated with decreased insulin resistance and systemic inflammation: an open label randomized prospective study from Eastern India. *Diabetes Res Clin Pract.* (2014) 103:e18–23. doi: 10.1016/j.diabres.2013.12.044

6. Sollid ST, Hutchinson MY, Fuskevåg OM, Figenschau Y, Joakimsen RM, Schirmer H, et al. No effect of high-dose vitamin D supplementation on glycemic status or cardiovascular risk factors in subjects with prediabetes. *Diabetes Care.* (2014) 37:2123–31. doi: 10.2337/dc14-0218

7. International Diabetes Federation. *IDF Diabetes Atlas, 10th Edn.* Brussels: International Diabetes Federation (2021).

8. Ye J, Wei W. The influence of dyslipidemia on the diabetes onset and its associated risk factors. *Chin J Lab Diagn*. (2011) 15:860–2. Available online at: https://kns.cnki.ne t/kcms2/article/abstract?v=3uoqlhG8C44YLTlOAiTRKgchrJ08w1e7tvjWANqNvpq5_qP55_MZVyZnEZuPhe9yz8KRU0dfZPGoRZiwbHTSuiZt96Yh5q&uniplatform=NZ KPT

9. Hutchinson MS, Figenschau Y, Njølstad I, Schirmer H, Jorde R. Serum 25-hydroxyvitamin D levels are inversely associated with glycated haemoglobin (HbA(1c)). *Scand J Clin Lab Inv.* (2011) 71:399–406. doi: 10.3109/00365513.2011.575235

10. Grimnes G, Figenschau Y, Almås B, Jorde R. Vitamin D, insulin secretion, sensitivity, and lipids: results from a case-control study and a randomized

controlled trial using hyperglycemic clamp technique. *Diabetes.* (2011) 60:2748–57. doi: 10.2337/db11-0650

11. Afzal S, Bojesen SE, Nordestgaard BG. Low 25-hydroxyvitamin D and risk of type 2 diabetes: a prospective cohort study and metaanalysis. *Clin Chem.* (2013) 59:381–91. doi: 10.1373/clinchem.2012.193003

12. Gunasekaran V, Srinivasan SK, Veintramuthu S. Assessment of vitamin d on metabolic disorders in arthritic prediabetic patients-a pharmacological approach. *Int J Pharm Sci Res.* (2016) 7:6.

13. Jafari T, Fallah AA, Barani A. Effects of vitamin D on serum lipid profile in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. *Clin Nutr.* (2016) 35:5. doi: 10.1016/j.clnu.2016.03.001

14. Kane L, Moore K, Lütjohann D, Bikle D, Schwartz JB. Vitamin D3 effects on lipids differ in statin and non-statin-treated humans: superiority of free 25-OH D levels in detecting relationships. *J Clin Endocrinol Metab.* (2013)98: 4400– 9. doi: 10.1210/jc.2013-1922

15. Oh J, Weng S, Felton SK, Bhandare S, Riek A, Butler B, et al. 1,25(OH) 2 vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. *Circulation.* (2009) 120:687–98. doi: 10.1161/CIRCULATIONAHA.109.856070

16. Wood RJ. Vitamin D and adipogenesis: new molecular insights. *Nutri Rev.* (2008) 66:40–46. doi: 10.1111/j.1753-4887.2007.00004.x

17. Mead JR, Irvine SA. Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. *J Mol Med.* (2002) 80:753–69. doi: 10.1007/s00109-002-0384-9

18. World Health Organization and International Diabetes Federation. *Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia: Report of a WHO/IDF Consultation.* Geneva: World Health Organization (2006).

19. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. (2004) 27: s5-s10. doi: 10.2337/diacare.27.2007.S5

20. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. *Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020).* New York, NY: John Wiley & Sons (2020).

21. Bhatt SP, Misra A, Pandey RM, Upadhyay AD, Gulati S, Singh N. Vitamin D supplementation in overweight/obese Asian Indian women with prediabetes reduces glycemic measures and truncal subcutaneous fat: a 78 weeks

randomized placebo-controlled trial (PREVENT-WIN Trial). Sci Rep. (2020) 10:220. doi: 10.1038/s41598-019-56904-y

22. Gerveieeha Z, Siassi F, Qorbani M, Ziaeian F, Sotoudeh G. The effect of different amounts of vitamin D supplementation on serum calcidiol, anthropometric status, and body composition in overweight or obese nursing women: a study protocol for a randomized placebo-controlled clinical trial. *Trials.* (2019) 20:542. doi: 10.1186/s13063-019-3622-y

23. Jorde R, Sollid ST, Svartberg J, Schirmer H, Joakimsen RM, Njølstad I. Vitamin D 20,000 IU per week for five years does not prevent progression from prediabetes to diabetes. *J Clin Endocrinol Metab.* (2016) 101:1647–55. doi: 10.1210/jc.2015-4013

24. Moreira-Lucas TS, Duncan AM, Rabasa-Lhoret R, Vieth R, Gibbs AL, Badawi A, et al. Effect of vitamin D supplementation on oral glucose tolerance in individuals with low vitamin D status and increased risk for developing type 2 diabetes (EVIDENCE): a double-blind, randomized, placebo-controlled clinical trial. *Diabetes Obes Metab.* (2016) 19:133–41. doi: 10.1111/dom.12794

25. Nagpal J, Pande JN, Bhartia A, A. double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. *Diab Med J Br Diab Assoc.* (2009) 26:19–27. doi: 10.1111/j.1464-5491.2008.02636.x

26. Hoseini SA, Aminorroaya A, Iraj B, Amini M. The effects of oral vitamin D on insulin resistance in pre-diabetic patients. *J Res Med Sci.* (2013) 18:47–51.

 Gannage-Yared MH, Azoury M, Mansour I, Baddoura R, Halaby G, Naaman R, et al. Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. J Endocrinol Invest. (2003) 26:748–53. doi: 10.1007/BF03347358

28. Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig H. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. *Osteoporosis Int.* (2009) 20:315–22. doi: 10.1007/s00198-008-0662-7

29. Davidson MB. Response to comment on: Davidson et al. High-dose vitamin D supplementation in people with prediabetes and hypovitaminosis D. *Diabetes Care.* (2013) 36:E72. doi: 10.2337/dc12-2225

30. Rajabi-Naeeni M, Dolatian M, Qorbani M, Vaezi AA. The effect of omega-3 and vitamin D co-supplementation on glycemic control and lipid profiles in reproductiveaged women with pre-diabetes and hypovitaminosis D: a randomized controlled trial. *Diabetol Metab Syndr*. (2020) 12:41. doi: 10.1186/s13098-020-00549-9

31. Misra P, Kant S, Misra A, Jha S, Kardam P, Thakur N, et al. Community based randomized controlled trial to see the effect of vitamin d supplementation on development of diabetes among women with prediabetes residing in a rural community of northern India. *J Family Med Prim Care.* (2021) 10:3122–9. doi: 10.4103/jfmpc_jfmpc_j11_21

32. Liu E, Meigs JB, Pittas AG, McKeown NM, Economos CD, Booth SL. Plasma 25-hydroxyvitamin d is associated with markers of the insulin resistant phenotype in nondiabetic adults. *J. Nutr.* (2009) 139:831. doi: 10.3945/jn.108.093831

33. AlAnouti F, Abboud M, Papandreou D, Mahboub N, Haidar S, Rizk R. Effects of vitamin D supplementation on lipid profile in adults with the metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials. *Nutrients*. (2020) 12:3352. doi: 10.3390/nu12113352

34. Qi KJ, Zhao ZT, Zhang W, Yang F. The impacts of vitamin D supplementation in adults with metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. *Front Pharmacol.* (2022) 13:1033026. doi: 10.3389/fphar.2022.1033026

35. Contreras-Bolívar V, García-Fontana B, García-Fontana C, Muñoz-Torres M. Mechanisms involved in the relationship between vitamin d and insulin resistance: impact on clinical practice. *Nutrients*. (2021) 13:3491. doi: 10.3390/nu13103491

36. Surdu AM, Pînzariu O, Ciobanu DM, Negru AG, Căinap SS, Lazea C. Vitamin D and its role in the lipid metabolism and the development of atherosclerosis. *Biomedicines.* (2021) 9:172. doi: 10.3390/biomedicines9020172

37. Fernández-Arroyo S, Hernández-Aguilera A, de Vries MA, Burggraaf B, van der Zwan E, Pouw N. Effect of Vitamin D3 on the postprandial lipid profile in obese patients: a nontargeted lipidomics study. *Nutrients.* (2019) 11:1194. doi: 10.3390/nu11051194

38. Faraji S, Alizadeh M. Mechanistic effects of vitamin d supplementation on metabolic syndrome components in patients with or without vitamin D deficiency. *J Obes Metab Syndr.* (2020) 29:270–80. doi: 10.7570/jomes20003

39. Szymczak-Pajor I, Sliwioska A. Analysis of association between vitamin D deficiency and insulin resistance. *Nutrients.* (2019) 11:794. doi: 10.3390/nu1104 0794

40. Muscogiuri G, Altieri B, Penna-Martinez M, Badenhoop K. Focus on vitamin D and the adrenal gland. *Horm Metab Res.* (2015) 47:239–46. doi: 10.1055/s-0034-1396893

41. McCarty MF, Thomas CA. PTH excess may promote weight gain by impeding catecholamine-induced lipolysis-implications for the impact of calcium, vitamin D, and alcohol on body weight. *Med Hypotheses.* (2003) 61:535–42. doi: 10.1016/S0306-9877(03)00227-5

42. Vranid L, Mikolaševid I, Milid S. Vitamin D deficiency: consequence or cause of obesity? *Medicina*. (2019) 55:541. doi: 10.3390/medicina55090541

43. Wamberg L, Christiansen T, Paulsen SK, Fisker S, Rask P, Rejnmark L, et al. Expression of vitamin D-metabolizing enzymes in human adipose tissue – the effect of obesity and diet-induced weight loss. *Int J Obes.* (2013) 37:651–7. doi: 10.1038/ijo.2012.112

44. Cordeiro A, Santos A, Bernardes M, Ramalho A, Martins MJ. Vitamin D metabolism in human adipose tissue: could it explain low vitamin D status in obesity? *Horm Mol Biol Clin Investig.* (2017) 18:33. doi: 10.1515/hmbci-2017-0003

45. Paschou SA, Kosmopoulos M, Nikas IP, Spartalis M, Kassi E, Goulis DG, et al. The impact of obesity on the association between vitamin d deficiency and cardiovascular disease. *Nutrients.* (2019) 11:2458. doi: 10.3390/nu11102458

46. Mirhosseini N, Rainsbury J, Kimball SM. Vitamin D supplementation, serum 25(OH)D concentrations and cardiovascular disease risk factors: a systematic review and meta-analysis. *Front Cardiovasc Med.* (2018) 5:87. doi: 10.3389/fcvm.2018.00087

47. Szymczak-Pajor I, Miazek K, Selmi A, Balcerczyk A, Sliwioska A. The action of vitamin D in adipose tissue: is there the link between vitamin D deficiency and adipose tissue-related metabolic disorders? *Int J Mol Sci.* (2022) 23:956. doi: 10.3390/ijms23020956

48. Harahap IA, Landrier JF, Suliburska J. Interrelationship between Vitamin D and calcium in obesity and its comorbid conditions. *Nutrients.* (2022) 14:3187. doi: 10.3390/nu14153187

49. Wierzbicka A, Oczkowicz M. Sex differences in vitamin D metabolism, serum levels and action. *Br J Nutr.* (2022) 128:2115–30. doi: 10.1017/S000711452200 0149

50. Gutiérrez OM, Farwell WR, Kermah D, Taylor EN. Racial differences in the relationship between vitamin d, bone mineral density, and parathyroid hormone in the national health and nutrition examination survey. *Osteoporos Int.* (2011) 22:1745–53. doi: 10.1007/s00198-010-1383-2

51. Schleicher RL, Sternberg MR, Looker AC, Yetley EA, Lacher DA, Sempos CT. National estimates of serum total 25-hydroxyvitamin d and metabolite concentrations measured by liquid chromatography-tandem mass spectrometry in the US population during 2007-2010. *J Nutr.* (2016) 146:1051–61. doi: 10.3945/jn.115.227728

52. Cashman KD, Ritz C, Adebayo FA, Dowling KG, Itkonen ST, Öhman T, et al. Differences in the dietary requirement for vitamin D among Caucasian and East African women at Northern latitude. *Eur J Nutr.* (2019) 58:2281–91. doi: 10.1007/s00394-018-1775-1

53. Man RE Li LJ, Cheng CY, Wong TY, Lamoureux E, Sabanayagam C. Prevalence and determinants of suboptimal vitamin D levels in a multiethnic Asian population. *Nutrients.* (2017) 9:313. doi: 10.3390/nu9030313

54. George JA, Norris SA, van Deventer HE, Pettifor JM, Crowther NJ. Effect of adiposity, season, diet and calcium or vitamin D supplementation on the vitamin D status of healthy urban African and Asian-Indian adults. *Br J Nutr.* (2014) 112:590–9. doi: 10.1017/S0007114514001202

55. El Khoudary SR, Samargandy S, Zeb I, Foster T, de Boer IH, Li D. Serum 25hydroxyvitamin-D and nonalcoholic fatty liver disease: Does race/ethnicity matter? Findings from the MESA cohort. *Nutr Metab Cardiovasc Dis.* (2020) 30:114– 22 doi: 10.1016/j.numecd.2019.09.004

56. Vaughan M, Trott M, Sapkota R, Premi G, Roberts J, Ubhi J, et al. Changes in 25-hydroxyvitamin D levels post-vitamin D supplementation in people of Black and Asian ethnicities and its implications during COVID-19 pandemic: a systematic review. *J Hum Nutr Diet.* (2022) 35:995–1005. doi: 10.1111/jhn.12949

57. Shea BJ, Reeves BC, Wells Gl. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ.* (2017) 358:j4008. doi: 10.1136/bmj.j4008